IP Library Granted Patent US 7,803,572
Granted Patent B2
US 7,803,572 · App. 10/562,290 · Granted Sep 28, 2010

Protease detection assay

Assignee: Atlas Genetics, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,572
App. No.
10/562,290
Granted
Sep 28, 2010
Kind
B2
Abstract

The invention provides methods and compounds for detecting protease activity in a sample solution comprising contacting the sample solution with a protease substrate labelled with an electrochemically active marker, providing conditions under which any protease which may be present in the sample may degrade the protease substrate and electrochemically determining information relating to the electrochemically active marker.

Claims (15)

1. A method for detecting protease activity in a sample solution comprising the steps of:

i) contacting the sample solution with a protease substrate labeled with an electrochemically active marker, wherein the electrochemically active marker is a metallocene moiety,

ii) providing conditions under which a protease present in the sample solution may degrade the protease substrate, wherein the protease is capable of recognizing the protease substrate, and

iii) electrochemically determining information relating to the electrochemically active marker, thereby detecting the protease activity in the sample.

2. A method as claimed in claim 1 wherein the information relating to the electrochemically active marker is determined using voltammetry.

3. A method as claimed in claim 2 wherein the information relating to the electrochemically active marker is determined using differential pulse voltammetry.

4. A method as claimed in claim 1 wherein the information relating to the electrochemically active marker is determined using an amperometric technique.

5. A method as claimed in claim 1 wherein the information relating to the electrochemically active marker is determined using a technique that utilizes one or more electrodes that are functionally surrounded by a selectively permeable membrane.

6. A method as claimed in claim 1 wherein the electrochemically active marker is a ferrocene moiety.

7. A method as claimed in claim 1 wherein the electrochemically active marker is attached to the protease substrate through a linker.

8. A method as claimed in claim 1 wherein each protease substrate molecule is, on average, labeled with more than one electrochemically active marker molecule.

9. A method as claimed in claim 1 wherein the protease substrate labeled with an electrochemically active marker is a single amino acid labeled with an electrochemically active marker.

10. A method for detecting a disease in a subject the method comprising the method of claim 1 further comprising a step of comparing said protease activity with a level of protease activity that is diagnostic of a disease in a subject, thereby detecting a disease in a subject.

11. A method for detecting a pathogen the method comprising the method of claim 1 further comprising a step of comparing said protease activity with a level of protease activity that is diagnostic of the presence of a pathogen, thereby detecting a pathogen.

12. A method for screening for a protease inhibitor the method comprising the method of claim 1 further comprising a step of contacting the sample solution with a putative protease inhibitor.

Assignments (6)
SECURITY INTEREST Recorded Mar 25, 2025
From: BINX HEALTH LIMITED
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 070620/0287 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2025
From: BX HEP AGGREGATOR, LLC,
To: BINX HEALTH LIMITED
Reel/Frame 069925/0466 →
ASSIGNMENT OF PATENT SECURITY AGREEMENT Recorded Oct 3, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: BX HEP AGGREGATOR, LLC
Reel/Frame 069107/0116 →
PATENT SECURITY AGREEMENT Recorded Apr 7, 2021
From: BINX HEALTH LIMITED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 055859/0724 →
CHANGE OF NAME Recorded Mar 25, 2021
From: ATLAS GENETICS LIMITED
To: BINX HEALTH LIMITED
Reel/Frame 055718/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2006
From: BRAVEN, HELEN; KEAY, RUSSELL; FLOWER, STEPHEN
To: ATLAS GENETICS, LTD.
Reel/Frame 018445/0066 →
Priority Claims (1)
GB 0316075.1 · Jul 9, 2003 · national
Continuity (1)
Related Publication 20060240503A1 · Oct 26, 2006